Why the study?
Does optimising antihypertensive and statin treatments reduce cardiovascular risk and improve life expectancy in an ethnically diverse urban population?
Does optimising antihypertensive and statin treatments reduce cardiovascular risk and improve life expectancy in an ethnically diverse urban population?
Optimising antihypertensive and statin therapies in a large urban population is a cost-effective strategy to reduce cardiovascular risk and improve life expectancy.
Answers are grounded in this paper and cite their sources.
Supports cost-effective optimization of CV treatments in diverse urban populations; leaves open the need for prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: